KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Goodwill: 2017-2025

Historic Goodwill for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $595.9 million.

  • Amneal Pharmaceuticals' Goodwill fell 0.40% to $595.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $595.9 million, marking a year-over-year decrease of 0.40%. This contributed to the annual value of $597.4 million for FY2024, which is 0.20% down from last year.
  • Amneal Pharmaceuticals' Goodwill amounted to $595.9 million in Q3 2025, which was down 0.24% from $597.4 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Goodwill ranged from a high of $602.9 million in Q1 2022 and a low of $522.8 million during Q1 2021.
  • For the 3-year period, Amneal Pharmaceuticals' Goodwill averaged around $598.1 million, with its median value being $598.5 million (2024).
  • In the last 5 years, Amneal Pharmaceuticals' Goodwill rose by 15.33% in 2022 and then fell by 0.62% in 2023.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Goodwill stood at $593.0 million in 2021, then climbed by 0.98% to $598.9 million in 2022, then declined by 0.04% to $598.6 million in 2023, then decreased by 0.20% to $597.4 million in 2024, then fell by 0.40% to $595.9 million in 2025.
  • Its Goodwill was $595.9 million in Q3 2025, compared to $597.4 million in Q2 2025 and $597.5 million in Q1 2025.